Oncology Nursing News

Ozekibart Shows Activity in Late-Line Colorectal Cancer

Updated interim findings from a phase 1/2 study evaluating ozekibart (INBRX-109) in combination with FOLFIRI demonstrate ...
Seeking Alpha

CytomX’s Varsetatug Masetecan (EpCAM PROBODY® ADC) Continues to Demonstrate Positive Data Supporting Potential as a New Treatment Option in Late-Line Colorectal Cancer

- Confirmed response rates in expansion cohorts of 32% at 10 mg/kg Q3W dose and 20% at 8.6 mg/kg Q3W - - Estimated progression free survival of 7.1 months at 10 mg/kg and 6.8 months at 8.6 mg/kg - ...
Business Wire

Arcus Presents New Data for its HIF-2a Inhibitor Casdatifan, Which Showed Progression-Free Survival Beyond One Year in Late-Line Kidney Cancer

Median progression-free survival (mPFS) was 15.1 months, and the confirmed overall response rate (cORR) increased to 45% for the 100mg QD (once daily) tablet cohort in an updated analysis of the ...
Hosted on MSN

Roche breast cancer drug improves survival of up to 62% in late-stage trial

Roche (OTCQX:RHHBY) subsidiary Genentech announced on Saturday that its experimental breast cancer therapy, giredestrant, as part of a combination regimen, reduced the risk of disease progression or ...
Business Wire

TUKYSA Added to First-Line Maintenance Therapy Extends Median Progression-Free Survival by Over 8 Months in Patients with HER2+ Metastatic Breast Cancer

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced detailed results from the Phase 3 HER2CLIMB-05 trial of the tyrosine kinase inhibitor TUKYSA ® (tucatinib) as part of an ...